[The role of immune checkpoint inhibitors in lung cancer: from clinical trials to clinical practice]

Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 12;43(2):95-99. doi: 10.3760/cma.j.issn.1001-0939.2020.02.006.
[Article in Chinese]

Abstract

肺癌是全球范围内发生率和死亡率最高的恶性肿瘤。近年来，免疫检查点抑制剂在非小细胞肺癌和小细胞肺癌的治疗中均有突破，改变了肺癌治疗策略的格局，也改善了患者的生存结局。本文对免疫检查点抑制剂在肺癌治疗中的使用时机、疗效、安全性和适用人群进行探讨。.

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Clinical Trials as Topic
  • Evidence-Based Medicine
  • Humans
  • Immunotherapy* / methods
  • Lung Neoplasms / immunology
  • Lung Neoplasms / therapy*
  • Programmed Cell Death 1 Receptor

Substances

  • Antineoplastic Agents, Immunological
  • Programmed Cell Death 1 Receptor